Quick Answer
Orchestra BioMed Holdings, Inc. reported Total Revenue of $33.48 million for fiscal year 2025.
Orchestra BioMed Holdings, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $33.48M | +1169.2% |
| 2024 | $2.64M | -4.4% |
| 2023 | $2.76M | -21.9% |
| 2022 | $3.53M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $861.0K | -12.8% | +3.0% |
| June 30, 2025 | $836.0K | +7.5% | -3.7% |
| March 31, 2025 | $868.0K | +40.0% | -12.1% |
| September 30, 2024 | $987.0K | +135.6% | +26.9% |
| June 30, 2024 | $778.0K | -15.0% | +25.5% |
| March 31, 2024 | $620.0K | -46.7% | +48.0% |
| September 30, 2023 | $419.0K | -64.0% | -54.2% |
| June 30, 2023 | $915.0K | +128.2% | -21.4% |
- Orchestra BioMed Holdings, Inc. showed an increase of +1169.2% in Total Revenue compared to the prior fiscal year.
- Over the 2022–2025 period, Orchestra BioMed Holdings, Inc.’s total revenue has grown by 847.7% (from $3.53 million to $33.48 million).
- The most recent figure is from Orchestra BioMed Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: